Cargando…

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

BACKGROUND: RZF is a novel antifungal of the echinocandin class with distinctive pharmacokinetics that support weekly dosing intervals. RZF is being developed for the treatment of candidemia and invasive candidiasis (IC) and the prevention of invasive fungal infections. A previously developed popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252571/
http://dx.doi.org/10.1093/ofid/ofy210.1221
_version_ 1783373293431029760
author Lakota, Elizabeth A
Ganesan, Harish
Flanagan, Shawn
Ong, Voon
Sandison, Taylor
Bhavnani, Sujata M
Rubino, Christopher M
Ambrose, Paul G
author_facet Lakota, Elizabeth A
Ganesan, Harish
Flanagan, Shawn
Ong, Voon
Sandison, Taylor
Bhavnani, Sujata M
Rubino, Christopher M
Ambrose, Paul G
author_sort Lakota, Elizabeth A
collection PubMed
description BACKGROUND: RZF is a novel antifungal of the echinocandin class with distinctive pharmacokinetics that support weekly dosing intervals. RZF is being developed for the treatment of candidemia and invasive candidiasis (IC) and the prevention of invasive fungal infections. A previously developed population PK model based on Phase 1 intravenous (IV) data [AAC 2018; e02603–17] was refined using IV data from additional Phase 1 and Phase 2 (STRIVE) studies. METHODS: Data from the two Phase 1 studies used previously to develop the model were pooled with data from an additional Phase 1 study and the STRIVE trial in patients with candidemia and/or IC. The population PK model was refined using NONMEM Version 7.2. The ability of covariates such as body size, age, sex, albumin, markers of liver and renal function, and infection status to explain a portion of the interindividual variability on select PK parameters was explored using stepwise forward selection (α = 0.01) and backward elimination (α = 0.001). The final model was externally validated by comparing model-based predictions to observed data from STRIVE, which were not available during model development. RESULTS: The final population PK model was a linear, four-compartment model with zero order IV input. Albumin was the most important predictor of the interindividual variability in RZF PK as significant relationships were found between serum albumin concentration and clearance, volume of the central compartment, volume of peripheral compartment 1, and volume of peripheral compartment 2. Additional relationships were found between PK parameters and sex, body weight, and infection status. The model provided precise and unbiased fits to the observed data (Figure 1). Differences in predicted median AUC across a wide range of covariate values were modest (Figure 2). The final model was also able to predict the central tendency and variability in RZF concentration–time data from patients with candidemia and/or IC not included in the model development (Figure 3). [Image: see text] [Image: see text] [Image: see text] CONCLUSION: A population PK model describing RZF PK in healthy subjects and patients with candidemia and/or IC was successfully developed. This model was utilized for subsequent PK-PD target attainment analyses to support dose selection for RZF. DISCLOSURES: E. A. Lakota, Cidara Therapeutics: Research Contractor, Research support. H. Ganesan, Cidara Therapeutics: Research Contractor, Research support. S. Flanagan, Cidara Therapeutics: Employee and Shareholder, Salary and stock options. V. Ong, Cidara Therapeutics: Employee and Shareholder, Salary and Stock options. T. Sandison, Cidara Therapeutics: Employee and Shareholder, Salary and Stock options. S. M. Bhavnani, Cidara Therapeutics: Research Contractor, Research support. C. M. Rubino, Cidara Therapeutics: Research Contractor, Research support. P. G. Ambrose, Cidara Therapeutics: Research Contractor, Research support.
format Online
Article
Text
id pubmed-6252571
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62525712018-11-28 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida Lakota, Elizabeth A Ganesan, Harish Flanagan, Shawn Ong, Voon Sandison, Taylor Bhavnani, Sujata M Rubino, Christopher M Ambrose, Paul G Open Forum Infect Dis Abstracts BACKGROUND: RZF is a novel antifungal of the echinocandin class with distinctive pharmacokinetics that support weekly dosing intervals. RZF is being developed for the treatment of candidemia and invasive candidiasis (IC) and the prevention of invasive fungal infections. A previously developed population PK model based on Phase 1 intravenous (IV) data [AAC 2018; e02603–17] was refined using IV data from additional Phase 1 and Phase 2 (STRIVE) studies. METHODS: Data from the two Phase 1 studies used previously to develop the model were pooled with data from an additional Phase 1 study and the STRIVE trial in patients with candidemia and/or IC. The population PK model was refined using NONMEM Version 7.2. The ability of covariates such as body size, age, sex, albumin, markers of liver and renal function, and infection status to explain a portion of the interindividual variability on select PK parameters was explored using stepwise forward selection (α = 0.01) and backward elimination (α = 0.001). The final model was externally validated by comparing model-based predictions to observed data from STRIVE, which were not available during model development. RESULTS: The final population PK model was a linear, four-compartment model with zero order IV input. Albumin was the most important predictor of the interindividual variability in RZF PK as significant relationships were found between serum albumin concentration and clearance, volume of the central compartment, volume of peripheral compartment 1, and volume of peripheral compartment 2. Additional relationships were found between PK parameters and sex, body weight, and infection status. The model provided precise and unbiased fits to the observed data (Figure 1). Differences in predicted median AUC across a wide range of covariate values were modest (Figure 2). The final model was also able to predict the central tendency and variability in RZF concentration–time data from patients with candidemia and/or IC not included in the model development (Figure 3). [Image: see text] [Image: see text] [Image: see text] CONCLUSION: A population PK model describing RZF PK in healthy subjects and patients with candidemia and/or IC was successfully developed. This model was utilized for subsequent PK-PD target attainment analyses to support dose selection for RZF. DISCLOSURES: E. A. Lakota, Cidara Therapeutics: Research Contractor, Research support. H. Ganesan, Cidara Therapeutics: Research Contractor, Research support. S. Flanagan, Cidara Therapeutics: Employee and Shareholder, Salary and stock options. V. Ong, Cidara Therapeutics: Employee and Shareholder, Salary and Stock options. T. Sandison, Cidara Therapeutics: Employee and Shareholder, Salary and Stock options. S. M. Bhavnani, Cidara Therapeutics: Research Contractor, Research support. C. M. Rubino, Cidara Therapeutics: Research Contractor, Research support. P. G. Ambrose, Cidara Therapeutics: Research Contractor, Research support. Oxford University Press 2018-11-26 /pmc/articles/PMC6252571/ http://dx.doi.org/10.1093/ofid/ofy210.1221 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lakota, Elizabeth A
Ganesan, Harish
Flanagan, Shawn
Ong, Voon
Sandison, Taylor
Bhavnani, Sujata M
Rubino, Christopher M
Ambrose, Paul G
1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title_full 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title_fullStr 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title_full_unstemmed 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title_short 1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
title_sort 1390. pharmacokinetic-pharmacodynamic (pk-pd) target attainment analyses to support rezafungin (rzf) dose selection in treatment of candida
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252571/
http://dx.doi.org/10.1093/ofid/ofy210.1221
work_keys_str_mv AT lakotaelizabetha 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT ganesanharish 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT flanaganshawn 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT ongvoon 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT sandisontaylor 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT bhavnanisujatam 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT rubinochristopherm 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida
AT ambrosepaulg 1390pharmacokineticpharmacodynamicpkpdtargetattainmentanalysestosupportrezafunginrzfdoseselectionintreatmentofcandida